William Blair Reaffirms Market Perform Rating for Eyenovia (NASDAQ:EYEN)

William Blair reiterated their market perform rating on shares of Eyenovia (NASDAQ:EYEN) in a research note issued to investors on Friday morning,Benzinga reports. William Blair also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.37) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Eyenovia in a research note on Wednesday, November 13th.

Eyenovia Stock Performance

Shares of EYEN opened at $0.10 on Friday. Eyenovia has a one year low of $0.09 and a one year high of $2.57. The business has a fifty day moving average of $0.49 and a 200 day moving average of $0.71. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.74 and a quick ratio of 0.27. The firm has a market capitalization of $6.53 million, a P/E ratio of -0.14 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative net margin of 114,639.41% and a negative return on equity of 1,108.24%. During the same quarter last year, the company posted ($0.18) earnings per share. As a group, sell-side analysts anticipate that Eyenovia will post -0.5 EPS for the current year.

Insider Transactions at Eyenovia

In other news, CEO Michael M. Rowe bought 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was bought at an average price of $0.57 per share, with a total value of $28,500.00. Following the acquisition, the chief executive officer now owns 82,927 shares of the company’s stock, valued at approximately $47,268.39. This represents a 151.85 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.10% of the company’s stock.

Hedge Funds Weigh In On Eyenovia

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its position in shares of Eyenovia by 1,444.4% during the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock worth $217,000 after purchasing an additional 205,390 shares in the last quarter. Vanguard Group Inc. boosted its stake in Eyenovia by 25.2% in the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after purchasing an additional 360,924 shares during the period. Armistice Capital LLC purchased a new stake in Eyenovia during the 2nd quarter valued at approximately $3,601,000. Ground Swell Capital LLC bought a new stake in shares of Eyenovia during the second quarter valued at approximately $27,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eyenovia in the second quarter worth $26,000. 25.84% of the stock is currently owned by hedge funds and other institutional investors.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.